OR WAIT 15 SECS
WuXi's Laboratory Testing Division will be the exclusive supplier of laboratory testing services for Hong Kong-based Lee's Pharm.
WuXi PharmaTech and Lee's Pharm, a research-based biopharmaceutical company headquartered in Hong Kong with operations in China, announced on Aug. 26, 2015 that the two companies have signed an agreement whereby WuXi's Laboratory Testing Division (LTD) will be the exclusive supplier of laboratory testing services for Lee's Pharm. These services will include LTD's entire portfolio of discovery and investigational new drug/new drug application package services, including chemistry analytical services, in-vitro and in-vivo biology, oncology, immunology, in-vitro ADME (absorption, distribution, metabolism, and excretion) studies, pharmacokinetic/pharmacodynamic studies, toxicology, and clinical bioanalysis. LTD will provide dedicated program management, streamline project coordination across WuXi, and allocate the necessary resources and R&D development efforts for Lee's Pharm programs.
"WuXi's impressive platform of lab testing services will allow our compounds to advance seamlessly through discovery, preclinical, and clinical development," Benjamin Li, executive director and CEO of Lee's Pharm, said in a press release.
Source: WuXi PharmaTech